drugset / Trial / NCT04224987

Azithromycin for Child Survival in Niger: Mortality and Resistance Trial

NCT04224987

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings.Targeting treatment to children 1-11 months old could reduce antimicrobial resistance by limiting antibiotic distributions while treating children at the highest mortality risk. However, this targeted intervention has not yet been tested. The AVENIR mortality/resistance trial aims to assess the efficacy of age-based targeting of biannual azithromycin distribution on mortality as well as determine the impact of age-based targeting on antimicrobial resistance.

Timeline

Start
2020-11-24
Primary completion
2024-07-31
Completion
2024-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 20 mg/kg Oral